Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 18
- Registration Number
- NCT04616248
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 308
- Registration Number
- NCT04600141
- Locations
- 🇧🇷
Fundação São Francisco Xavier, Ipatinga, Minas Gerais, Brazil
🇧🇷UNIMED Varginha, Varginha, Minas Gerais, Brazil
🇧🇷Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT04580121
- Locations
- 🇮🇹
Ospedale Santa Chiara; Unita Operativa Di Ematologia, Pisa, Toscana, Italy
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT04564001
TocIlizumab in Chronic Antibody-mediated Rejection in Kidney Transplant Recipients
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 50
- Registration Number
- NCT04561986
- Locations
- 🇸🇪
Transplant Center, Sahlgrenska University Hospital, Gothenburg, Vastra Gotaland Regioin, Sweden
🇸🇪Skåne University Hospital, Malmo, Skåne, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Tocilizumab in COVID-19 Lahore General Hospital
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Lahore General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04560205
- Locations
- 🇵🇰
Lahore General Hospital, Lahore, Punjab, Pakistan
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04551352
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
- Conditions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT04547062
- Locations
- 🇫🇷
CHU of Nantes, Nantes, France
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30432
- Registration Number
- NCT04529863
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Center for East; West Medicine, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.